Kither Biotech is a pre-clinical stage company developing new therapies for rare pulmonary diseases with high unmet needs. The company leverages its unique expertise in delivery of signal transduction inhibition to the respiratory system, leading to strongly improved delivery to the lung.
The key product is a proprietary compound to treat Cystic Fibrosis (CF) with preclinical data showing strong superiority vs. the current market leader, with the potential to radically change the treatment paradigm of CF, a global market projected to grow in excess of $20 billion. The CF program is in pre-clinical phase and a Phase I/IIa clinical trial in early 2022.
The pipeline also includes a proprietary a small molecule that has shown strong results in pre-clinical models for Idiopathic Pulmonary Fibrosis (IPF), a lethal orphan disease, and has potential long-term use with COVID-19 patients. The company plans to launch the preclinical phases of the this program in early 2021.